BAYRHO-D MINI-DOSE Rx
Generic Name and Formulations:
Rho(D) immune globulin human 50mcg; for IM inj.
- Selinexor Shows Clinical Activity, Toxicity in Multiple Myeloma
- Cabozantinib Yields Similar QoL Outcomes to Everolimus in Renal Cell Carcinoma
- Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma
- Hodgkin Lymphoma Treatment Regimens
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Diffuse Large B-Cell Lymphoma
- Recommended Immunization Schedule for Ages 0 to 18 Years
Indications for BAYRHO-D MINI-DOSE:
Prevention of Rho(D) sensitization following termination of pregnancies up to 12 weeks gestation.
Each syringe (approx. 50mcg) prevents sensitization to 2.5mL of Rh positive red blood cells. Give IM up to 12 weeks' gestation, within 3 hours of an Rh incompatible delivery, miscarriage, or abortion.
Rho(D) positive patients. Pregnancy (Cat.C).
Live vaccines. Have epinephrine available.
Full Dose (single-dose syringes and vials)—1, 10; Mini-Dose (single-dose syringes)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML